We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Royal Gold (RGLD) Provides Updates on Operations for Q3
Read MoreHide Full Article
Royal Gold, Inc. (RGLD - Free Report) has provided an update on third-quarter fiscal 2018 (ended Mar 31, 2018) operations. During the quarter, RGLD Gold AG, the fully-owned subsidiary of Royal Gold, sold roughly 63,000 gold equivalent ounces consisting of roughly 49,000 gold ounces, 272,000 silver ounces and 2,000 tons of copper related to its streaming agreements. The company ended the quarter with 26,000 ounces of gold and 659,000 ounces of silver, highlighting a sequential increase owing to late received deliveries.
Average realized prices of gold and silver were $1,328 and $16.77 per ounce sold compared with the prior-quarter figures of $1,272 and $16.79, respectively. Average realized copper prices were $6,902 per ton compared with $6,746 in the prior-year quarter.
In the fiscal third quarter, cost of sales was roughly $342 per gold equivalent ounce, up from prior-quarter figure of $319. The cost of sales is based on the quarterly average silver-gold ratio of roughly 79 to 1 and gold-copper ratio of around 0.19 ton per ounce.
Royal Gold’s fiscal third-quarter deliveries were not impacted by the temporary shutdown of the mill processing facility at Mount Milligan occurring in early calendar 2018. However, the company expects this shutdown to impact its mid-calendar 2018 results as some of the gold and copper deliveries expected in June through August will be deferred to a later date.
During the fiscal third quarter, Royal Gold paid back $75 million of the outstanding balance amount on its revolving credit facility. As of Mar 31, 2018, the revolver had $75 million outstanding, which translates into available revolver capacity of $925 million.
Shares of Royal Gold have moved up 2.2% over the past three months, outperforming the industry’s 10.9% decline.
Zacks Rank & Stocks to Consider
Royal Gold currently carries a Zacks Rank #3 (Hold).
ArcelorMittal has an expected long-term earnings growth rate of 13.4%. Its shares have soared 45.1% over a year.
Daqo New Energy has an expected long-term earnings growth rate of 7%. Its shares have rallied a whopping 220% over a year.
CF Industries has an expected long-term earnings growth rate of 6%. Its shares have gained 30.2% over a year.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Royal Gold (RGLD) Provides Updates on Operations for Q3
Royal Gold, Inc. (RGLD - Free Report) has provided an update on third-quarter fiscal 2018 (ended Mar 31, 2018) operations. During the quarter, RGLD Gold AG, the fully-owned subsidiary of Royal Gold, sold roughly 63,000 gold equivalent ounces consisting of roughly 49,000 gold ounces, 272,000 silver ounces and 2,000 tons of copper related to its streaming agreements. The company ended the quarter with 26,000 ounces of gold and 659,000 ounces of silver, highlighting a sequential increase owing to late received deliveries.
Average realized prices of gold and silver were $1,328 and $16.77 per ounce sold compared with the prior-quarter figures of $1,272 and $16.79, respectively. Average realized copper prices were $6,902 per ton compared with $6,746 in the prior-year quarter.
In the fiscal third quarter, cost of sales was roughly $342 per gold equivalent ounce, up from prior-quarter figure of $319. The cost of sales is based on the quarterly average silver-gold ratio of roughly 79 to 1 and gold-copper ratio of around 0.19 ton per ounce.
Royal Gold’s fiscal third-quarter deliveries were not impacted by the temporary shutdown of the mill processing facility at Mount Milligan occurring in early calendar 2018. However, the company expects this shutdown to impact its mid-calendar 2018 results as some of the gold and copper deliveries expected in June through August will be deferred to a later date.
During the fiscal third quarter, Royal Gold paid back $75 million of the outstanding balance amount on its revolving credit facility. As of Mar 31, 2018, the revolver had $75 million outstanding, which translates into available revolver capacity of $925 million.
Shares of Royal Gold have moved up 2.2% over the past three months, outperforming the industry’s 10.9% decline.
Zacks Rank & Stocks to Consider
Royal Gold currently carries a Zacks Rank #3 (Hold).
Some stocks worth considering in the basic materials space are ArcelorMittal (MT - Free Report) , Daqo New Energy Corp. (DQ - Free Report) and CF Industries Holdings, Inc. (CF - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
ArcelorMittal has an expected long-term earnings growth rate of 13.4%. Its shares have soared 45.1% over a year.
Daqo New Energy has an expected long-term earnings growth rate of 7%. Its shares have rallied a whopping 220% over a year.
CF Industries has an expected long-term earnings growth rate of 6%. Its shares have gained 30.2% over a year.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>